Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Letrozole +/- Fluzoparib in ER+, Platinum-Sensitive Recurrent Ovarian Cancer
NCT07000344Terminated
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fluzoparib in ovarian cancer (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoint: 6-month progression-free survival rate. Started Jul 2025; status: terminated.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07000344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000344.